Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence.

Published byGundi Braun Modified over 5 years ago

Similar presentations

Presentation on theme: "Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence."— Presentation transcript:

1 Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence of Insulins, Acarbose, GLP-1 analogues, Meglitinides and SGLT-2 inhibitors. **For detailed figures on point estimates and CIs, please consult online supplementary appendix 5. Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence of Insulins, Acarbose, GLP-1 analogues, Meglitinides and SGLT-2 inhibitors. **For detailed figures on point estimates and CIs, please consult online supplementary appendix 5. Manuj Sharma et al. BMJ Open 2016;6:e010210 ©2016 by British Medical Journal Publishing Group

Download ppt "Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence."

Similar presentations

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Insulin Therapy for Type 2 Diabetes Mellitus JAMA.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Insulin Therapy for Type 2 Diabetes Mellitus JAMA.
Associations between OHS/OKS and hospital readmission costs >12 months after THR. Costs are measured in 2014 pound sterling (£). Associations between OHS/OKS.

Associations between OHS/OKS and hospital readmission costs >12 months after THR. Costs are measured in 2014 pound sterling (£). Associations between OHS/OKS.
SGLT2 Inhibitors: What Do the Data Mean for My Patients?

SGLT2 Inhibitors: What Do the Data Mean for My Patients?
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.
Number of local authorities (LAs) commissioning each service directly or indirectly (n=148) (*Flu vaccination data excludes the service commissioned across.

Number of local authorities (LAs) commissioning each service directly or indirectly (n=148) (*Flu vaccination data excludes the service commissioned across.
Mean expense per year on courses and conferences that trainees have not been reimbursed. Mean expense per year on courses and conferences that trainees.

Mean expense per year on courses and conferences that trainees have not been reimbursed. Mean expense per year on courses and conferences that trainees.
Daily contribution (%) of sodium and potassium from major food groups among participants aged 8–12 years (n=517), which includes major food groups provided.

Daily contribution (%) of sodium and potassium from major food groups among participants aged 8–12 years (n=517), which includes major food groups provided.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Antihyperglycemic therapy in type 2 diabetes: general recommendations

Antihyperglycemic therapy in type 2 diabetes: general recommendations
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Bar charts comparing the results of ePROMs between patients who found the scores inadequately assessed their symptoms against all other patients leaving.

Bar charts comparing the results of ePROMs between patients who found the scores inadequately assessed their symptoms against all other patients leaving.
Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in.

Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in.
Scatter graph showing total work time equivalent of all specialist palliative care practitioners commissioned by the Clinical Commissioning Group (CCG)

Scatter graph showing total work time equivalent of all specialist palliative care practitioners commissioned by the Clinical Commissioning Group (CCG)
(A) Indirectly age-sex-deprivation-ethnicity standardised procedure ratios for combined eye injection procedures (OPCS-4: C794 and C893) by CCG in England,

(A) Indirectly age-sex-deprivation-ethnicity standardised procedure ratios for combined eye injection procedures (OPCS-4: C794 and C893) by CCG in England,
DSM-IV delirium prevalence, including the estimated delirium prevalence in the 31 patients that did not undergo delirium assessment following initial screening.

DSM-IV delirium prevalence, including the estimated delirium prevalence in the 31 patients that did not undergo delirium assessment following initial screening.
Scatter graph showing the total number of specialist palliative care beds commissioned compared with the estimated number of people with palliative care.

Scatter graph showing the total number of specialist palliative care beds commissioned compared with the estimated number of people with palliative care.
Estimated probability of successful quitting (quit attempt of longer than 1 year) by quit attempt number in the Ontario Tobacco Survey. Estimated probability.

Estimated probability of successful quitting (quit attempt of longer than 1 year) by quit attempt number in the Ontario Tobacco Survey. Estimated probability.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Similar presentations

Ads by Google